Pharma’s DTC channel of choice is (and likely will remain for some time) TV. IQVIA estimates pharma spent over $6 billion on DTC TV advertising campaigns for 75 brands spending over $10 million each in 2024 alone. IQVIA estimates drug companies spent nearly $50 billion on DTC TV advertising campaigns over the past decade. TV’s heyday may be behind us, but television itself is not going anywhere. What is happening behind the curtain with the economics of all this TV spending, however, is starting to become quite painful. Behind exploding promotional budgets, IQVIA recently announced that DTC promotional spending grew roughly 50% as launch ROI took a major hit from media saturation and rising market-access barriers.
Prescription drug marketing wasn’t always so complex. For years, marketing experts preached a simple formula: hire sales reps, pour money into physician promotion, run a TV ad campaign, build patient awareness, and hope consumers enter their physician’s office demanding the brand. Today, that model isn’t obsolete, but it is becoming much more difficult to defend. Prescriptive drug marketing is evolving from mass-market promotion to a fractured, data-driven, omnichannel approach in which patients go from Google to social media to online patient communities to their doctor’s offices and back online again. The problem for pharmaceutical marketers is that consumers have changed faster than many pharma marketing organizations.
The patient may see a commercial, visit a product website, Google the drug, read Reddit posts, watch patient videos, check their insurance coverage and then ask their doctor about a medication. But none of those things mean a prescription will be written, covered, or filled. Prior authorization hurdles, formulary restrictions, step therapy, copays, physician preferences and other competitor products can halt the patient at any step along that process. That’s why pharma marketers need to stop treating “patient interest” like it’s marketing success in a bottle. The true funnel doesn’t end with “ask your doctor.” It concludes when the right patient actually initiates — and sticks with — therapy.
Think about what’s happened to patient-acquisition economics.
IQVIA estimates that DTC spending for drugs launched in 2018 averaged about $2,700 per patient start during the first 24 months after launch. For launches in 2022, that number had jumped to nearly $13,000 per patient acquired – a 375% increase. Some brands reportedly spent over $80,000 on DTC advertising for every patient they acquired. More astonishingly, nine specialty products launched in 20 22 together pulled in $1.3 billion in combined gross sales during their first two years on the market while spending roughly $1.1 billion on DTC advertising. Sales forces. HCP promotion. Patient-support programs. Rebates. Discounts. Remember those expenses too.
This is the uncomfortable question pharma marketers need to ask: Are we generating demand, or are we buying increasingly expensive awareness?
Television still has enormous value for the right product. IQVIA’s analysis found that specialty brands spending at least $1 million on DTC averaged nearly twice as many patients per provider as brands that didn’t advertise directly to consumers. But the same analysis concludes that DTC ROI at launch has been declining for more than a decade. The lesson isn’t that TV doesn’t work. It’s that “TV works” is no longer a sufficient media strategy.
The Patient Has Become the Media Planner
The modern prescription drug consumer is not linear like the marketer’s funnel on PowerPoint. If someone sees a TV commercial about a GLP-1 drug, oncology therapy or immunology medication, they can grab their smartphone before the ad finishes. Minutes later, they can access the manufacturer’s website, prescribing information, patient forums, doctor videos, news articles, TikTok clips, Reddit threads and testimonials from patients who experienced side effects or had insurance coverage denied for the drug.
Pharma marketing is changing. Brands can no longer dictate their story.
The linear Path of Traditional DTC:
PRESCRIPTION ADVERTISEMENTS → WEBSITE → PHYSICIAN CONVERSATION
The modern pharma patient exists in an information ecosystem where corporate advertising is one of many voices—and often not the most respected one. That’s also why one of the biggest hurdles for DTC marketers going forward isn’t media fragmentation. It’s how to earn credibility.
Today’s consumers understand that pharma advertising is meant to sell them something. They hear cheerful jingles while a robotic voice quickly lists serious side effects. They watch happy, smiling patients going about their day, wondering how much the drug costs. Now they’re juxtaposing this content with real-world conversations on social media. The FDA has also cracked down on how risk information is presented on TV and radio ads. “As of Nov. 20, 2024, covered DTC TV ads must present the major statement concerning side effects and contraindications in a manner that is clear, conspicuous and delivered using a neutral presentation. For TV ads, this means both an audio AND text presentation that meet certain requirements.
They don’t trust Pharma marketers. And that’s exactly why they should. But regulatory compliance and consumer trust are different. An advertisement can satisfy FDA requirements and still fail the patient’s credibility test.
Targeting Is Evolving. Attribution Is Broken.
Digital media provides pharma marketers with targeting capabilities that television advertisers could only dream of: audience segmentation, behavioral targeting, connected TV, sequential messaging, search marketing and sophisticated analytics. It’s like marketing nirvana until someone asks a simple question: Did our advertising cause incremental prescriptions?
Attribution. That’s much harder.
A patient might see a television commercial, receive a digital ad impression, search for the disease, visit a brand website and eventually pick up a prescription three months later. Which channel gets credit? Worse yet, what if that patient was already thinking about treatment because their doctor brought it up? Marketing attribution can turn correlation into causation in an instant.
Pharma marketing needs to get smarter about this stuff. Impressions, website visits, click-through rates, and video completion rates are useful metrics. They’re great for diagnosing problems. But they’re not tied to business outcomes. Direct-to-consumer (DTC) organizations will need to measure incremental patient starts, cost per qualified patient, HCP response rates, abandonment/persistence, payer friction and actual net revenue generated for every dollar spent marketing.
If a campaign brings 500,000 visitors to a website but few incremental treated patients, marketing may still have been very successful… at driving traffic.
Access Is Now Part of Marketing
Arguably the biggest evolution in prescription drug marketing is one many brand teams still push aside: access is now a marketing issue.
Think about launching a product and spending millions telling consumers to ask their physicians about your drug, only to have them learn from the doctor’s office that their insurer won’t cover it, their copay is too expensive or they have to fail another treatment first. Sure, those are payer issues. But from the patient’s perspective, that’s their experience with the brand.
It’s becoming even more important as companies spend more money driving consumer demand. IQVIA recently reported that average cumulative DTC spending during the first three years after launch rose from approximately $140 million for products launched between 2015 and 2018 to $169 million for medicines launched between 2019 and 20″2. That’s a nearly 21% increase. Spending $169 million to build demand makes little sense if no one has figured out what happens when newly interested patients try to enter the treatment funnel.
The best DTC marketers won’t focus only on advertising budgets. They’ll partner across marketing, analytics, medical, sales, patient services and market access to figure out where interested patients are getting lost.
Pharma Has Too Much Attention
Here’s another issue that doesn’t get enough discussion: too many pharma companies are fighting over the same pool of consumer attention.
The biggest offender? Drug ads. Literally. There are too many of them.
Some therapeutic categories are worse than others. Immunology comes to mind. According to IQVIA, approximately one-third of all U.S. DTC advertising spending this year will go toward immune-related conditions. Fifteen individual brands will spend at least $10 million each on television. When that many brands targeting similar patients start spending tens or hundreds of millions of dollars on advertising, low-single-digit increases in share of voice become astronomically expensive.
The natural inclination is to counter-program. Spend more.
Counter-programming might still work. If everyone is airing ten ads, run fifteen.
But the smarter play might be to demand more relevance.
Too many advertisers are still asking, “How many people can we reach?” Marketers should start asking, “Which patients need to see this information right now?” A patient newly diagnosed with rheumatoid arthritis doesn’t need to see the same thing as someone who has failed two biologics. Mom searching for answers about Alzheimer’s disease needs different information than her husband does. And both of them need different resources than patients researching migraine prevention. Add insurance companies into the mix, and it gets even more complicated.
We’re confusing patients and wasting money by treating all of these people like “target consumers.” It also means we’ll continue producing forgettable advertising.
DTC’s Next Chapter Won’t Feel Like Advertising
Look, I like advertising as much as anyone. I get excited when the first sparkly Chrysler 200 commercial airs every year. I think BMW has nailed their US trailer ads since someone finally let them drive without lyrics. And I actually laughed out loud the first time I saw Hulu’s Emmy commercial.
But effective pharmaceutical marketing won’t feel like those campaigns.
The future of DTC is likely to feel less like advertising and more like patient navigation. Pharma brands will build awareness as they do now, but the successful brands will spend more time helping consumers navigate the information gap between seeing an ad and deciding to start treatment. That includes understanding:
Do my symptoms warrant a visit to a physician?
What treatment options are available?
How does this drug work? How is it different than other drugs I’ve heard about?
What questions should I ask my doctor?
Will my insurance cover this medication, and what will it cost me?
What happens if my insurance denies coverage?
How do I start treatment?
What should I expect after I start this medication? What happens if I don’t see results?
And that list doesn’t even include consideration for issues like affordability, access or physician abandonment.
That’s a far cry from telling patients to “ask your doctor.” And it won’t work unless pharmaceutical companies are just as focused on connecting the dots between consumer marketing and HCP marketing. You can drive consumer demand with TV and digital ads all you want, but if physicians aren’t primed by those efforts — if doctors don’t understand the clinical data, aren’t sure which patients are appropriate, fear access issues or aren’t prepared to handle questions from newly educated patients — then consumer awareness rarely turns into new patients.
TV vs. digital isn’t the story of DTC’s evolution. It’s going to sound basic by now, but targeting vs. attribution will determine which companies succeed over the next few years. Television, search, social media, connected TV, patient communities, and emerging AI-driven discovery tools all have a place in DTC. Reach vs. relevance. Banner ads vs. journeys. Promoting your product vs. helping patients understand their diagnosis and treatment options.
Advertising will still matter. Pharma companies are still spending hundreds of millions of dollars convincing patients to take their medications. Direct-to-consumer marketing clearly works. Patients see ads and then doctors write more prescriptions.
Patient acquisition costs are rising faster than most brands ever anticipated, however. If you’re spending more money to acquire every new patient, you know spending isn’t getting more efficient. You’re just getting better at wasting money.
The most important question for DTC brand teams to ask in 2026 isn’t “How much should we spend?” It’s “Where did that patient go after we captured their attention?”
Got more questions than answers? That means you’re heading in the right direction.
